Cargando…
ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential
Highly selective N-type voltage-gated calcium (Ca(V)) channel inhibitors from cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Molecular Diversity Preservation International (MDPI)
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663408/ |
| _version_ | 1782270990765522944 |
|---|---|
| author | Schroeder, Christina I. Lewis, Richard J. |
| author_facet | Schroeder, Christina I. Lewis, Richard J. |
| author_sort | Schroeder, Christina I. |
| collection | PubMed |
| description | Highly selective N-type voltage-gated calcium (Ca(V)) channel inhibitors from cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ω-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain. |
| format | Online Article Text |
| id | pubmed-3663408 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2006 |
| publisher | Molecular Diversity Preservation International (MDPI) |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-36634082013-05-28 ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential Schroeder, Christina I. Lewis, Richard J. Mar Drugs Review Highly selective N-type voltage-gated calcium (Ca(V)) channel inhibitors from cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ω-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain. Molecular Diversity Preservation International (MDPI) 2006-04-06 /pmc/articles/PMC3663408/ Text en © 2006 by MDPI Reproduction is permitted for noncommercial purposes. |
| spellingShingle | Review Schroeder, Christina I. Lewis, Richard J. ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential |
| title | ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential |
| title_full | ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential |
| title_fullStr | ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential |
| title_full_unstemmed | ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential |
| title_short | ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential |
| title_sort | ω-conotoxins gvia, mviia and cvid: sar and clinical potential |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663408/ |
| work_keys_str_mv | AT schroederchristinai ōconotoxinsgviamviiaandcvidsarandclinicalpotential AT lewisrichardj ōconotoxinsgviamviiaandcvidsarandclinicalpotential |